To hear about similar clinical trials, please enter your email below
Trial Title:
Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image
NCT ID:
NCT05627297
Condition:
Hepatocellular Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
CEUS and CEMRI
Description:
contrast-enhanced ultrasound and contrast-enhanced MRI examination
Arm group label:
RFA
Arm group label:
SR
Summary:
This study intends to establish two prognostic models based on contrast-enhanced
ultrasound (CEUS) and dynamic enhanced magnetic resonance (DE-MRI) multimodal images:
prognostic model of liver cancer patients after hepatectomy and prognostic model of liver
cancer patients after radiofrequency ablation. Combined with artificial intelligence
imaging omics, traditional imaging omics and clinical information, to predict and compare
the prognosis of two different treatment methods for early liver cancer, so as to realize
the individual selection of treatment methods for early liver cancer patients
Criteria for eligibility:
Study pop:
200
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Primary single hepatocellular carcinoma confirmed by histology or cytology, with a
maximum diameter ≤5.0 cm;
- Good liver function, Child-Pugh grade A;
- No serious dysfunction of heart, lung, kidney and other important organs ④
Liver resection or radiofrequency ablation was performed in our hospital,
and the study protocol and follow-up procedure were followed.
Exclusion Criteria:
- Patients who cannot perform DCE-MRI examination due to metal implants in the body ②
Patients who had received other treatment before DCE-MRI or CEUS;
- Invisible lesions, diffuse lesions or poor DCE-MRI/CEUS image quality under
CEUS; ④ Drug abuse, clinical or psychological or social factors that make
informed consent or study implementation affected.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Nanjing Drum Tower Hospital
Address:
City:
Nanjing
Zip:
210009
Country:
China
Status:
Recruiting
Contact:
Last name:
Wentao Kong, Dr
Phone:
13815897824
Email:
breezewem@163.com
Start date:
December 1, 2022
Completion date:
November 1, 2025
Lead sponsor:
Agency:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Agency class:
Other
Source:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05627297
